Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

One of the world's biggest global health funders will ask the private sector for a steep increase in donations as concern of ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...

Atomi Financial Group Inc. trimmed its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...

Japan’s market growth accelerates through dynamic clinical partnerships, biologic breakthroughs, and automated facilities.

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...

Brown & Brown's fourth-quarter revenue beat analyst expectations as commissions and fees rose. The insurance company said profit fell to $210 million from $269 million a year earlier, though adjusted ...

Health Canada has granted market authorisation to Takeda Canada for FRUZAQLA (fruquintinib) capsules to treat adults with ...

Takeda Pharmaceuticals Inc. struck a more somber tone in 2024, undergoing a “significant, multiyear efficiency program” to navigate short-term generic competition and get back to ...